Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Lori Freedman Acquires 9,022 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) insider Lori Freedman bought 9,022 shares of Organogenesis stock in a transaction dated Friday, June 6th. The stock was purchased at an average cost of $2.99 per share, for a total transaction of $26,975.78. Following the purchase, the insider now owns 846,459 shares of the company's stock, valued at approximately $2,530,912.41. This trade represents a 1.08% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Lori Freedman also recently made the following trade(s):

• On Thursday, June 5th, Lori Freedman acquired 142,379 shares of Organogenesis stock. The stock was purchased at an average cost of $2.91 per share, with a total value of $414,322.89.
• On Wednesday, June 4th, Lori Freedman bought 100,863 shares of Organogenesis stock. The shares were acquired at an average cost of $2.82 per share, for a total transaction of $284,433.66.

Organogenesis Trading Up 13.5%

ORGO stock traded up $0.41 during mid-day trading on Monday, reaching $3.44. The company had a trading volume of 2,247,351 shares, compared to its average volume of 1,150,852. Organogenesis Holdings Inc. has a 12 month low of $2.28 and a 12 month high of $6.71. The company has a market capitalization of $436.38 million, a PE ratio of -57.33 and a beta of 1.63. The firm has a 50 day moving average of $3.82 and a 200 day moving average of $3.85. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The firm had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. On average, equities analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley increased their target price on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research note on Wednesday, March 5th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in Organogenesis in the fourth quarter worth $38,000. Merit Financial Group LLC purchased a new position in Organogenesis during the 1st quarter worth $45,000. Palumbo Wealth Management LLC acquired a new position in Organogenesis during the 4th quarter valued at about $65,000. ProShare Advisors LLC increased its position in Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after buying an additional 6,689 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Organogenesis in the first quarter valued at about $67,000. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.